GELS (Gelteq) LT-Debt-to-Total-Asset: 0.00 (As of Jun. 2025)


GELS Gelteq Ltd GELS
10 GF Score
Price $0.69
! 3 Warning Signs
View Full Analysis

What is Gelteq LT-Debt-to-Total-Asset?

Gelteq GELS +7.88% 10 LT-Debt-to-Total-Asset is 0.00 as of Jun. 2025. GuruFocus rates GELS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gelteq's long-term debt to total assests ratio for the quarter that ended in Jun. 2025 was 0.00.

Gelteq's long-term debt to total assets ratio declined from Jun. 2024 (0.09) to Jun. 2025 (0.00). It may suggest that Gelteq is progressively becoming less dependent on debt to grow their business.

Gelteq  (NAS:GELS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Gelteq LT-Debt-to-Total-Asset Related Terms

Gelteq LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Gelteq's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelteq LT-Debt-to-Total-Asset Chart

Gelteq Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.01 0.06 0.11 0.09 0.00

Gelteq Semi-Annual Data
Jun20 Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 0.11 0.00 0.09 0.00 0.00
GELS
10GF Score
Gelteq Ltd GELS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gelteq LT-Debt-to-Total-Asset Calculation

Gelteq's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )/Total Assets (A: Jun. 2025 )
=0.009/13.981
=0.00

Gelteq's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (Q: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2025 )/Total Assets (Q: Jun. 2025 )
=0.009/13.981
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Gelteq (GELS) has a LT-Debt-to-Total-Asset of 0.00 as of Jun. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gelteq and its competitors.
Is Gelteq's LT-Debt-to-Total-Asset too high?
Gelteq's current LT-Debt-to-Total-Asset is 0.00. Overall, Gelteq has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's LT-Debt-to-Total-Asset compare to YCBD and AKAN?
Gelteq's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gelteq and its competitors. Gelteq's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Gelteq's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Gelteq (GELS), the current LT-Debt-to-Total-Asset is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelteq Business Description

Address 644 Chapel Street, Level 19, South Yarra, VIC, AUS, 3141
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
10GF Score

Get the complete analysis for GELS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.69
Price